MBRS portfolios
Indication-centered sets of assets and competitors, searchable by company, asset or indication. Each packet is organized around a selected primary asset.
ABOUT MBRS
Biology at the center of drug-development risk.
MBRS—Mechanistic and Biological Risk Surface—provides a standardized, independently computed perspective on asset–indication fit, differentiation and competitive development risk.
THE PRINCIPLE
A company's core value is its asset. An asset's core value is its biology.
Our work is to surface that biology and assess where it supports an asset's position, where it creates constraints, and where competing programs may change the development picture. Biology is evaluated using a common lens across programs, modalities, indications and stages, rather than relying exclusively on sponsor narratives or market consensus.
THE COMPUTATION
A biological AI, not an LLM score generator.
Core MBRS scoring is derived from mechanistic and biological computation. Submitted documents provide evidence and context that may be mapped into the biological system; they do not simply prompt a language model to decide whether a drug will succeed. Narrative reports explain the calculated picture and its remaining uncertainties.
THE PRODUCT
From a single asset to its surrounding ecosystem.
MBRS AI
Private submission of relevant program evidence for biological mapping and ecosystem processing, subject to account approval and dataset readiness.
MBRS Analyst
Program summaries, evidence provenance, version history, score context and dated report issuances.
Independent phase references
Separate Phase I, II and III development-progression bands are labeled as independent research references, not MBRS-derived or validated asset-specific approval odds.
WHY IT EXISTS
An independent voice for diligence.
Drug-development ecosystems shift over time. New modalities, competitors, data and biological findings can challenge decisions made years earlier. MBRS is designed to provide a repeatable biology-focused perspective for portfolio review, program triage, comparative diligence, and investigation of potential combinations or alternative indications.
MBRS assessments are models and hypotheses, not experimental validation or substitutes for primary evidence. They are intended to inform—not replace—scientific, clinical, regulatory and commercial diligence.
See the system in context.
How It Works describes the document-to-portfolio workflow. Methods explains the biological scoring and validation framework.